KR20190131068A - 인간화된 항-cxcr5 항체를 사용하는 루푸스의 치료 - Google Patents

인간화된 항-cxcr5 항체를 사용하는 루푸스의 치료 Download PDF

Info

Publication number
KR20190131068A
KR20190131068A KR1020197030748A KR20197030748A KR20190131068A KR 20190131068 A KR20190131068 A KR 20190131068A KR 1020197030748 A KR1020197030748 A KR 1020197030748A KR 20197030748 A KR20197030748 A KR 20197030748A KR 20190131068 A KR20190131068 A KR 20190131068A
Authority
KR
South Korea
Prior art keywords
seq
antibody
amino acid
patients
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020197030748A
Other languages
English (en)
Korean (ko)
Inventor
제프리 밍
모셰 이. 질버스테인
로지에 카리미 안더레시
Original Assignee
사노피
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 사노피 filed Critical 사노피
Priority to KR1020257011427A priority Critical patent/KR20250052493A/ko
Priority claimed from PCT/EP2018/057310 external-priority patent/WO2018172465A1/en
Publication of KR20190131068A publication Critical patent/KR20190131068A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
KR1020197030748A 2017-03-22 2018-03-22 인간화된 항-cxcr5 항체를 사용하는 루푸스의 치료 Ceased KR20190131068A (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020257011427A KR20250052493A (ko) 2017-03-22 2018-03-22 인간화된 항-cxcr5 항체를 사용하는 루푸스의 치료

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762475173P 2017-03-22 2017-03-22
US62/475,173 2017-03-22
EP17306079 2017-08-18
EP17306079.9 2017-08-18
PCT/EP2018/057310 WO2018172465A1 (en) 2017-03-22 2018-03-22 Treatment of lupus using humanized anti-cxcr5 antibodies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020257011427A Division KR20250052493A (ko) 2017-03-22 2018-03-22 인간화된 항-cxcr5 항체를 사용하는 루푸스의 치료

Publications (1)

Publication Number Publication Date
KR20190131068A true KR20190131068A (ko) 2019-11-25

Family

ID=61827719

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020197030748A Ceased KR20190131068A (ko) 2017-03-22 2018-03-22 인간화된 항-cxcr5 항체를 사용하는 루푸스의 치료
KR1020257011427A Pending KR20250052493A (ko) 2017-03-22 2018-03-22 인간화된 항-cxcr5 항체를 사용하는 루푸스의 치료

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020257011427A Pending KR20250052493A (ko) 2017-03-22 2018-03-22 인간화된 항-cxcr5 항체를 사용하는 루푸스의 치료

Country Status (7)

Country Link
US (1) US20240207397A1 (https=)
EP (1) EP3601344A1 (https=)
JP (3) JP2020514386A (https=)
KR (2) KR20190131068A (https=)
CN (1) CN110662767A (https=)
AU (1) AU2018238540B2 (https=)
IL (2) IL318907A (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023010483A1 (en) * 2021-08-05 2023-02-09 Hifibio (Hk) Limited Anti-human cxcr5 antibody and uses thereof
WO2021216505A1 (en) * 2020-04-21 2021-10-28 Regeneron Pharmaceuticals, Inc. Non-human animals having a humanized cxcl13 gene

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111909273B (zh) * 2007-08-29 2024-03-26 塞诺菲-安万特股份有限公司 人源化的抗-cxcr5抗体、其衍生物及它们的应用
WO2012010582A1 (en) * 2010-07-21 2012-01-26 Roche Glycart Ag Anti-cxcr5 antibodies and methods of use
AU2015305850A1 (en) * 2014-08-22 2017-04-06 Sorrento Therapeutics, Inc. Antigen binding proteins that bind CXCR5

Also Published As

Publication number Publication date
IL269419A (en) 2019-11-28
KR20250052493A (ko) 2025-04-18
JP2025087764A (ja) 2025-06-10
IL318907A (en) 2025-04-01
EP3601344A1 (en) 2020-02-05
JP2023040241A (ja) 2023-03-22
AU2018238540A1 (en) 2019-11-07
JP2020514386A (ja) 2020-05-21
CN110662767A (zh) 2020-01-07
US20240207397A1 (en) 2024-06-27
AU2018238540B2 (en) 2025-02-27

Similar Documents

Publication Publication Date Title
JP5926162B2 (ja) 炎症傷害の処置および評価
JP5905534B2 (ja) 多発性硬化症を治療する方法
EP3237447B1 (en) Anti-csf1r antibodies for treating pvns
JP2008544960A5 (https=)
EP3348569B1 (en) Pan elr+ cxc chemokine antibodies
JP2011144204A (ja) インターフェロン−βを使用する腎不全のための治療法
JP2025087764A (ja) ヒト化抗ｃｘｃｒ５抗体を使用するループスの処置
JP2022539785A (ja) ＴＡＣＩ－Ｆｃ融合タンパク質及びその用途
US12577310B2 (en) Caninized antibodies to canine interleukin-31 receptor alpha
JP7727633B2 (ja) イヌインターロイキン－４受容体αに対する抗体
CN116059345A (zh) 方法、方案、组合和拮抗剂
JP2025000638A (ja) 抗ＩＦＮ－α／ω抗体の投与方法
US20210077619A1 (en) Treatment of lupus using humanized anti-cxcr5 antibodies
US20090068102A1 (en) Treating stroke
CN120693172A (zh) 用于治疗补体介导的疾病的与因子h融合的抗c5抗体
WO2024011946A1 (en) Polypeptide dimers for the treatment of systemic sclerosis
CN120960440A (zh) 用白喉毒素-人白细胞介素-3缀合物与其它药剂组合治疗骨髓增生性肿瘤的组合治疗方法
US12409208B2 (en) Treating tissue fibrosis with interleukin 24
CN121909046A (zh) 脱发病症的治疗
JP2025529248A (ja) 単純ヘルペスウイルス感染の処置
HK40108366A (zh) 使用激活素受体ii型信号传导抑制剂的方法
JP2021038198A (ja) 抗ｃ５抗体クロバリマブの使用によるｃ５関連疾患の治療または予防のための薬用量および投与レジメン
KR20180095013A (ko) 사멸 수용체 작용제로 전신성 경화증 완화

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20191018

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20210322

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20230703

Patent event code: PE09021S01D

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20231129

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20241107

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D